Dr. Lee is a specialist in Interventional Pulmonary and serves as the Wang Interventional Pulmonary Fellowship Director. His areas of clinical expertise include interventional pulmonology, pleural disease, minimal invasive diagnostics and lung cancer at Johns Hopkins. He also has extensive experience in the minimally invasive management of malignant airway obstruction, complex airway management and difficulty airways. In addition, he specializes in the diagnosis and management of pleural diseases and symptom relief with minimally invasive procedures. He is a fellow of the American College of Chest Physicians and the Johns Hopkins Master of Education for Health Professionals. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Pleural Effusion, Lung Nodules, Lymphofollicular Hyperplasia, Endoscopy, and Advanced Bronchoscopy.

Dr. Yarmus is a Professor of Medicine and Oncology and the director of Interventional Pulmonology at the Johns Hopkins University School of Medicine as well as the Vice Chair of Medicine for Strategy and Finance. He is an expert in the minimally invasive diagnosis and treatment of lung cancer and he leads the Interventional Pulmonary research program at Johns Hopkins with research investigating innovative minimally invasive device development and early-stage bronchoscopic treatments. He also has extensive experience in the minimally invasive management of malignant airway obstruction, complex airway management, pleural diseases and symptom relief with minimally invasive procedures such as indwelling pleural catheters and pleurodesis. Dr. Yarmus is a member of the Fleischner Society and a fellow of the American College of Chest Physicians and the American Thoracic Society. Dr. Yarmus is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Pleural Effusion, Lung Nodules, Lymphofollicular Hyperplasia, Endoscopy, and Advanced Bronchoscopy.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Charles Yim is a Radiologist in Towson, Maryland. Dr. Yim is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Ascites, Lymphofollicular Hyperplasia, Pleurisy, Bone Marrow Aspiration, and Gastrostomy.

Dr. Howard Steiner is an instructor of medicine at the Johns Hopkins School of Medicine. He has been practicing pulmonary and sleep consultative medicine since 1989. In his role as a diagnostician, he guides the evaluation and management of respiratory problems including infectious, malignant, allergic, autoimmune, and sleep-related disorders. He has been part-time faculty in the Johns Hopkins Pulmonary Division since 1991, is a Fellow in the American College of Chest Physicians, and mentors medical students, residents, and pulmonary fellows training at the Johns Hopkins Hospital. Contact for Research Inquiries 10755 Falls Road Pavilion I, Suite 200 Lutherville, MD 21093 Phone: (410) 583-7124 Selected Publications Lwebuga-Mukasa JS, Steiner H. Monoclonal antibody to rat lung Maclura Pomifera agglutinin (MPA) lectin binding glycoprotein localizes apically on rat and human type II pneumocytes and Clara cells. J Cell Biol 107:71a, 1989. Roberts PJ, McBean GJ, Steiner H, Kohler C, Schwarcz R. Lesioning Effects of Ibotenate in the immature rat brain and protection by 2-amino-7 phosphonoheptanoic acid. Soc Neurosci Abst 9:261, 1983. Steiner H, Ingbar DI. Mechanisms of lung injury and repair. In: Matthay RA, Matthay MA, Wiedemann HP eds. Annual Review of Pulmonary and Critical Care Medicine. Hanley & Belfus (Philadelphia, 1989), pp 205-223. Steiner H, Lwebuga-Mukasa JS. A549 cells display distinct functional and morphologic properties depending on their culture substratum. J Cell Biol 107:71a, 1989. Steiner H, Lwebuga-Mukasa JS. A549 cells produce a factor which is Mitogenic for human lung fibroblasts. Amer Rev Resp Dis 139:A492 1989. Steiner H, McBean GJ, Kohler C, Roberts PJ, Schwarcz R. Ibotenate Induced neuronal degeneration in immature rat brain. Brain Research 307:117-124, 1984. Dr. Steiner is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Bronchiectasis, Obstructive Sleep Apnea, Lung Metastases, and Interstitial Lung Disease.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Matthew Woodford is an Intensive Care Medicine provider in Towson, Maryland. Dr. Woodford has been practicing medicine for over 18 years and is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Emphysema, Bullae, Pneumonia, and Acute Interstitial Pneumonia.

Stephanie Wappel is an Intensive Care Medicine provider in Towson, Maryland. Dr. Wappel is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Obstructive Sleep Apnea, Drowsiness, Excessive Daytime Sleepiness, and Kuru.

Donald Slack is an Intensive Care Medicine provider in Baltimore, Maryland. Dr. Slack is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Pneumonia, Lung Metastases, Interstitial Lung Disease, Thyroidectomy, and Advanced Bronchoscopy.

Samuel Minkove is a Pulmonary Medicine provider in Towson, Maryland. Dr. Minkove is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Severe Acute Respiratory Syndrome (SARS), COVID-19, Pneumonia, Lymphofollicular Hyperplasia, and Vagotomy.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist in Lutherville, Maryland. Dr. Kalra has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

William Han is an Intensive Care Medicine provider in Baltimore, Maryland. Dr. Han is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Cancer, Lymphofollicular Hyperplasia, and Advanced Bronchoscopy.

Christine Argento is a Pulmonary Medicine provider in Baltimore, Maryland. Dr. Argento is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Pleural Effusion, Lymphofollicular Hyperplasia, Lung Nodules, Endoscopy, and Gastrostomy.

Dr. Mullen attended the University of Virginia, graduating in 1987 with a BA in Chemistry and Spanish. She then attended medical school at Columbia University College of Physicians and Surgeons, graduating in 1991. After an internship in Internal Medicine at the Hospital of the University of Pennsylvania, she returned to Columbia Presbyterian Medical Center (now New York Presbyterian Hospital) for her residency in Diagnostic Radiology. She served at Co-Chief Resident from 1995 to 1996. Dr. Mullen completed her fellowship in Cross-Sectional Imaging (Ultrasound, CT and MRI) at Johns Hopkins Hospital in 1997. Dr. Mullen worked in private practice for 5 years, gaining experience in general radiology, and developing interest and expertise in breast imaging, women's imaging, and body imaging. She joined Johns Hopkins Radiology in 2002, and has been based at Johns Hopkins Imaging at Green Spring. Dr. Mullen has expertise in screening and diagnostic mammography, breast ultrasound, breast MRI, and breast interventional procedures, as well as general ultrasound and bone densitometry. Dr. Mullen is interested in clinical breast imaging and resident and fellow education. She has been the Breast Imaging Fellowship Director since 2013. Dr. Mullen is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Fibrocystic Breast Disease, Lymphofollicular Hyperplasia, Osteopenia, and Melorheostosis with Osteopoikilosis.

Jeffrey Thiboutot is a primary care provider, practicing in Pulmonary Medicine in Baltimore, Maryland. Dr. Thiboutot is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lung Nodules, Pleurisy, Lymphofollicular Hyperplasia, Lung Cancer, and Endoscopy.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Dr. Zambidis is Associate Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Zambidis’ clinical expertise is in the treatment of disorders of the immune system, histiocytic disorders, hematologic malignancies, blood and bone marrow transplantation (BMT), and regenerative medicine. His research interest focuses on advancing our understanding of pluripotent stem cells– the ‘master’ stem cells that can generate any new cell or tissue that the body needs to repair itself. Dr. Zambidis earned his M.D./Ph.D. in the Medical Scientist Training Program at the University of Rochester, Rochester, N.Y. He completed his Pediatrics Residency in the Department of Pediatrics, Washington University, St. Louis, Missouri, and his clinical/research fellowships in Pediatric Hematology/Oncology at the Johns Hopkins Hospital and the National Cancer Institute at the NIH. Dr. Zambidis has been interested in the biology of stem cells since he came to Johns Hopkins, in 2001. As a Pediatric Hematology/Oncology fellow, he was one of the very first Hopkins investigators to work with human embryonic stem cells (hESCs), beginning shortly after they were made available to the biomedical research community, in 2002. Dr. Zambidis was awarded the first NIH K08 Clinician-Scientist Training Award specifically investigating the therapeutic potential of human pluripotent stem cells (2004). After joining the Hopkins faculty, in 2005, he developed an experimental model of the early formation process of human blood and blood vessels using human pluripotent stem cells. The Zambidis laboratory at the Johns Hopkins Institute for Cell Engineering focuses on understanding the developmental biology of human hemato-vascular and human pluripotent stem cells. More recently, his group completed studies on highly efficient methods for generating nonintegrated, human induced pluripotent stem cell (hiPSC) lines from myeloid progenitors. His group has developed novel hiPSC-based vascular therapies for retinopathies, and more recently derived a new class of human pluripotent stem cells in a naïve ground state with new functionalities with even greater potency and stronger regenerative capacities. As a BMT physician-scientist, his long-term goal is to use hESC, hiPSC, and related pluripotent stem cell technologies to not only treat severe degenerative diseases, but also to elucidate the biological nature of cancer and aging. Dr. Zambidis is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Gaucher Disease, Reticulohistiocytoma, Rosai-Dorfman Disease, and Lymphofollicular Hyperplasia.

Dr. Satomi Kawamoto is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. She specializes in computed tomography (CT), ultrasound, and image-guided biopsy. Dr. Kawamoto received her M.D. from Gunma University in Gunma, Japan, and subsequently completed two residencies, one in internal medicine at St. Luke’s International Hospital in Tokyo, and a second in diagnostic radiology at Johns Hopkins. She received a postdoctoral fellowship in cross-sectional imaging at Johns Hopkins, and then joined the Johns Hopkins faculty. Dr. Kawamoto’s research focuses on body CT and biopsy, particularly imaging of the genitourinary and gastrointestinal systems. Dr. Kawamoto is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Neuroendocrine Tumor, Muscle Invasive Bladder Cancer, Cavernous Lymphangioma, Hepato-Pancreato-Biliary Surgery, and Pancreaticoduodenectomy.

Dr. Emily Ambinder is an Assistant Professor and Division Chief of Breast Imaging in the Johns Hopkins Medicine Department of Radiology and Radiological Science. She specializes in all aspects of breast imaging including mammography, tomosynthesis, breast ultrasound, breast MRI, and image-guided breast procedures. Dr. Ambinder graduated from Emory College in 2008 with a degree in Chemistry and Mathematics. She then attended Emory School of Medicine, and spent an additional year completing a Master’s of Science in Clinical Research at Emory's Laney Graduate School. After a preliminary internal medicine internship at the Greater Baltimore Medical Center, she attended diagnostic radiology residency at Johns Hopkins. Dr. Ambinder graduated radiology residency in 2018. Following residency, she completed a year-long fellowship in Breast Imaging at Johns Hopkins. Dr. Ambinder's research focuses on improving breast cancer detection, with a focus on new technologies and public health. She joins the Johns Hopkins faculty in August 2019. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Fibrocystic Breast Disease, Lymphofollicular Hyperplasia, Fibroadenoma, and Breast Lump.

Dr. Elliot K. Fishman is a Professor in the Johns Hopkins Medicine Department Radiology and Radiological Science, Department of Oncology and Department of Surgery. He serves as a member of the Johns Hopkins Kimmel Cancer Center. His clinical and research interests focus on medical imaging with specific emphasis on three-dimensional (3D) imaging and computed tomography (CT). Dr. Fishman received his B.S. in 1973 and M.D. in 1977 from the University of Maryland. After a residency at Sinai Hospital in Baltimore, he completed a fellowship in CT at Johns Hopkins in 1980 and joined the Johns Hopkins faculty in 1981 as an Assistant Professor. In 1986, he became Associate Professor and, in 1991, Professor of Radiology and Oncology. He is a leader in the development of 3D imaging and rendering, including its impacts on and uses in patient care and management. He was involved from the beginning in the development of 3D imaging through his work with Pixar, which was a spin-off from LucasFilms in San Rafael, California. Over the last 25 years, Dr. Fishman continued to help develop 3D imaging and has been a leader in the development of interactive 3D rendering. His team is consistently at the forefront of research and development of new visualization and post-processing techniques and technologies. Dr. Fishman's extensive body of work in CT has resulted in over 1,000 peer-reviewed publications, and he is the author or co-author of 10 textbooks. He is the recipient of three prestigious Aunt Minnie Awards, honoring his outstanding contributions as both an educator and researcher. In 2007, he was named by Medical Imaging Magazine as the Top Radiologist in the Nation. He is a member of editorial boards for more than 35 journals, an active member of several professional radiology associations and is a past-president of the Society of Body CT/MR. Dr. Fishman is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma, Cavernous Lymphangioma, Pancreaticoduodenectomy, and Pancreatectomy.